AMOEBA (EPA:ALMIB) - Amoéba: BASF evaluates Amoeba's biocontrol products

Transparency directive : regulatory news

31/03/2020 08:30

PRESS RELEASE

                  BASF evaluates Amoeba's biocontrol products

Chassieu (France), March 31, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the signature of a Material Transfer Agreement (MTA) with BASF, one
of the leaders in biocontrol in France

The purpose of the research partnership is the provision by Amoéba of
experimental products containing the amoeba lysate Willaertia magna C2c Maky.
In return, the BASF group will carry out its own field and greenhouse trials to
evaluate the performance of these products in preventing fungal diseases on a
range of crops.

Amoéba and BASF are thus embarking on a targeted research phase which, if
successful, could promote the commercial development of biocontrol solutions.

"The use of our biocontrol solutions for trials on new types of crops, aims at
diversifying and enriching alternative solutions in crop protection. This new
partnership between Amoeba and BASF, which is present alongside farmers
worldwide through its "Agricultural Solutions" division, illustrates the
growing interest in the research work carried out by Amoeba over the past 10
years. These large-scale tests, with a world leader in the chemical industry,
offer significant value-added potential for the company and are an essential
step towards a possible commercial partnership". explains Fabrice Plasson,
Chairman and CEO of Amoéba.

Amoéba points out that the company is still in the testing phase for its
biocide and biocontrol applications and does not currently market any
products.

About BASF's Agricultural Solutions Division
With a rapidly growing population, the world is increasingly dependent on our
ability to develop sustainable agriculture that respects the environment. To
make this possible, we work with farmers, agricultural professionals, crop
protection specialists and others. That's why we invest in a strong research
pipeline and a broad product portfolio, which includes seeds and genetics,
chemical and biological crop protection, soil management, plant health, pest
control and digital agriculture. Our teams of experts, whether in the field,
laboratories or production sites, bridge the gap between innovation and
practical action to develop real ideas that work around the world, for farmers,
society and the planet. In 2019, our division generated more than EUR7.8
billion in sales. For more information, visit www.agriculture.basf.com or
follow us on our social media.

About BASF Group
At BASF, we create chemistry for a sustainable future. We combine economic
success with social responsibility and environmental protection. More than
117,000 employees in the BASF Group work on contributing to the success of our
customers in nearly all sectors and in almost every country in the world. Our
portfolio is organized into six segments: Chemicals, Materials, Industrial
Solutions, Surface Technologies, Nutrition and Care, and Agricultural
Solutions. In 2019, BASF generated sales of approximately EUR59 billion. BASF
shares are traded on the Frankfurt Stock Exchange (BAS) and under the name
American Depositary Receipts (BASFY) in the USA. For further information:
www.basf.com or www.basf.fr.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3) : BCC Research, "Markets for Advanced Wound Management Technologies,"
      Wellesley, MA, 2017
(4) : Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contact media BSF France - Agro division:
Cecile ACCARY - cecile.accary@basf.com - +33(0)6 70 48 81 49

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - Amoéba: BASF evaluates Amoeba's biocontrol products

Transparency directive : regulatory news

AMOEBA's latest news

Other stories